Publication date: Nov 28, 2019
During a study into the gut microbiome, investigators have discovered a microRNA (a small RNA molecule) that increases during peak disease in a mouse model of multiple sclerosis (MS) and in untreated MS patients.
This may unlock a new way of treating MS as when a synthetic version of the microRNA was orally given to the mice, it prevented disease.
-We’ve discovered a new mechanism to regulate the microbiome and treat a human disease that hadn’t been known before,” said senior author Howard Weiner, MD. -Our findings, which show that a microRNA can be used to target and influence the microbiome with precision, may have applicability for MS and many other diseases, including diabetes, ALS, obesity and cancer. “
Weiner, lead author Shirong Liu, MD, PhD and their colleagues investigated how the altered gut microbiome affects the course of MS. To do so, they studied the microbiome and microRNAs found in the experimental autoimmune encephalomyelitis (EAE) model of MS. They found that when they transferred fecal matter from EAE mice at peak disease, it protected the mice who received the transfer.
|disease||MESH||experimental autoimmune encephalomyelitis|